Table 1.

Ongoing clinical trials on drugs targeting metabolism for glioblastoma patients.

Indication	Trial	Phase	Drug	Number of patients	Primary Endpoint	Status
Newly diagnosed GBM	NCT04945148 - OPTIMUM	2	RT + TMZ + Met	64	PFS	Ongoing
Newly diagnosed GBM	NCT05929495	2	Adjuvant TMZ + Met	25	PFS at 6 months	Ongoing
Newly diagnosed GBM Recurrent GBM	NCT05183204	2	Met + Paxalisib + KD	33	PFS at 6 months	Ongoing
Newly diagnosed GBM Recurrent GBM	NCT03151772	1	Met + Disulfiram	3	Bioavailabilty of disulfiram and Met	Terminated
Newly diagnosed GBM	NCT02780024 - M-HARTT STUDY	2	Neoadjuvant Met + TMZ Hypofractionated RT + TMZ + Met Adjuvant TMZ + Met	50	Number of patients completing treatment	Ongoing
Recurrent GBM	NCT05120284	2a	DCA 1 weeks prior surgery depending on genotype	40	Efficacy on tumor PDC phosphorylation	Ongoing
GBM DMG AA G3 DIPG GC	NCT03243461 - HIT-HGG-2013	3	TMZ + VA	167	EFS	Ongoing
Recurrent GBM	NCT02648633	1	SBRT + Nivolumab + VA	4	Toxicity	Stop

GBM, Glioblastoma; RT, Radiotherapy; TMZ, Temozolomide; Met, Metformin; PFS, progression-free survival; KT, Ketogenic diet; DCA, Dichloroacetate; PDC, Pyruvate Dehydrogenase Complex; DMG, Diffuse midline glioma histone 3 K27M mutated; AA, anaplastic astrocytoma; DIPG, Diffuse intrinsic pontine glioma; GC, gliomatosis cerebri; SBRT, Stereotactic Body Radiation Therapy.